Gene therapy for cancer.

SELECTED CASES CASE 1. —A 26-year-old woman was referred to the Surgery Branch, National Cancer Institute, Bethesda, Md, with metastatic melanoma. A year earlier the patient had noted an enlarging mole on her right upper extremity; the results of the biopsy revealed a melanoma. She underwent a wide local excision and right axillary lymph node dissection. Of 30 lymph nodes, two contained melanoma. Despite experimental treatment with vaccinia tumor oncolysate, her disease progressed. On presentation to the National Institutes of Health in June 1989, she had about 30 subcutaneous deposits of melanoma, multiple lung metastases, and oral lesions on her tonsils and soft palate. On June 21,1989, she underwent resection of six separate subcutaneous lesions ranging in diameter from 2 to 5 cm to harvest tumor-infiltrating lymphocytes (TIL) (T cells that infiltrate into animal and human tumors and can be grown in culture with interleukin 2 [IL-2]). 1 Eight days

[1]  S. Rosenberg,et al.  Immunotherapy and gene therapy of cancer. , 1991, Advances in surgery.

[2]  S. Rosenberg,et al.  Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Rosenberg,et al.  Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. , 1992, Journal of immunology.

[4]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[5]  S. Rosenberg,et al.  Common Expression of Melanoma Tumor-Associated Antigens Recognized by Human Tumor Infiltrating Lymphocytes: Analysis by Human Lymphocyte Antigen Restriction , 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[6]  A. Asher,et al.  Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. , 1991, Journal of immunology.

[7]  M. Colombo,et al.  Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo , 1991, The Journal of experimental medicine.

[8]  K. Cornetta,et al.  Safety issues related to retroviral-mediated gene transfer in humans. , 1991, Human gene therapy.

[9]  E. Gilboa,et al.  Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. , 1990, Cancer research.

[10]  K. Cornetta,et al.  Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. , 1990, The New England journal of medicine.

[11]  B. Vogelstein,et al.  Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response , 1990, Cell.

[12]  K. Cornetta,et al.  Human gene transfer: characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[13]  M. Kriegler Gene Transfer and Expression: A Laboratory Manual , 1990 .

[14]  Z. Eshhar,et al.  Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[15]  S. Rosenberg,et al.  In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. , 1989, Journal of the National Cancer Institute.

[16]  T. Friedmann,et al.  Progress toward human gene therapy. , 1989, Science.

[17]  P. Leder,et al.  Murine interleukin-4 displays potent anti-tumor activity in vivo , 1989, Cell.

[18]  S M Larson,et al.  Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[20]  M. Bender,et al.  Evidence that the packaging signal of Moloney murine leukemia virus extends into the gag region , 1987, Journal of virology.

[21]  S. Rosenberg,et al.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. , 1986, Science.